Data Highlighting Advaxis’ ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Meeting

PRINCETON, N.J.--()--Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that The American Society of Clinical Oncology has accepted the abstract titled “ADXS-PSA plus pembrolizumab (pembro) in metastatic castration-resistant prostate cancer (mCRPC)” for a poster discussion at their annual meeting to be held June 1-5, 2018 in Chicago. The discussion will be presented and lead by author and principle investigator of the study, Mark Stein, MD, medical oncologist at Columbia University Medical Center.

“ADXS-PSA plus pembrolizumab (pembro) in metastatic castration-resistant prostate cancer (mCRPC)”

Title:

    “ADXS-PSA plus pembrolizumab (pembro) in metastatic castration-resistant prostate cancer (mCRPC)”

Abstract Number:

5019

Session:

Genitourinary (Prostate) Cancer

Date:

June 2, 2018 4:45 PM-6:00 PM

Presenter:

Mark Stein, MD
 

About ADXS—PSA

ADXS—PSA is currently being evaluated in a Phase 1/2 open-label, multicenter dose determination and expansion trial in patients with previously treated metastatic, castration-resistant prostate cancer. The trial is being conducted in a clinical trial collaboration and supply agreement with Merck & Co.

About Advaxis, Inc.

Advaxis, Inc. is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T cells to eliminate tumors. Advaxis has four franchises in various stages of clinical and preclinical development: HPV-associated cancers, neoantigen therapy, hotspot/ cancer antigens and prostate cancer.

To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, and YouTube.

Advaxis Forward-Looking Statement

This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis’ ability to develop and commercialize the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis’ proprietary immunotherapies. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis’ SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2017, and on Form 10-Q for the quarter ended January 31, 2018, which are available at www.sec.gov.

Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

Contacts

Advaxis, Inc.
Noelle Heber, 609-250-7575
Sr. Director Corporate Communications and Government Affairs
Heber@advaxis.com
or
Media:
Stern Strategy Group
Brian Hyland, 908-325-3891
Bhyland@sternstrategy.com
or
Rachel Auerbach, 908-325-3898
Rauerbach@sternstrategy.com
or
Investors:
LHA Investor Relations
Miriam Weber Miller, 212-838-3777
mmiller@lhai.com

Recent Stories

RSS feed for Advaxis, Inc.

Advaxis, Inc.